In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of Candida spp., Including 315 Isolates Resistant to Fluconazole
Open Access
- 1 November 2005
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 43 (11) , 5425-5427
- https://doi.org/10.1128/jcm.43.11.5425-5427.2005
Abstract
Anidulafungin is an echinocandin antifungal agent with potent activity against Candida spp. We assessed the in vitro activity of anidulafungin against 2,235 clinical isolates of Candida spp. using the CLSI broth microdilution method. Anidulafungin was very active against Candida spp. (the MIC at which 90% of strains are inhibited [MIC 90 ] was 2 μg/ml when MIC endpoint criteria of partial inhibition [MIC-2] were used). Candida albicans , C. glabrata , C. tropicalis , C. krusei , and C. kefyr were the most susceptible species of Candida (MIC 90 , 0.06 to 0.12 μg/ml), and C. parapsilosis , C. lusitaniae , and C. guilliermondii were the least susceptible (MIC 90 , 0.5 to 2 μg/ml). In addition, 315 fluconazole-resistant isolates were tested, and 99% were inhibited by ≤1 μg/ml of anidulafungin. These results provide further evidence for the spectrum and potency of anidulafungin activity against a large and geographically diverse collection of clinically important isolates of Candida spp.Keywords
This publication has 15 references indexed in Scilit:
- Anidulafungin: an echinocandin antifungalExpert Opinion on Investigational Drugs, 2004
- Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus SpeciesJournal of Clinical Microbiology, 2004
- Further Standardization of Broth Microdilution Methodology for In Vitro Susceptibility Testing of Caspofungin against Candida Species by Use of an International Collection of More than 3,000 Clinical IsolatesJournal of Clinical Microbiology, 2004
- Phase 2, Randomized, Dose-Ranging Study Evaluating the Safety and Efficacy of Anidulafungin in Invasive Candidiasis and CandidemiaAntimicrobial Agents and Chemotherapy, 2004
- Caspofungin Activity against Clinical Isolates of Fluconazole-Resistant CandidaJournal of Clinical Microbiology, 2003
- Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United StatesAntimicrobial Agents and Chemotherapy, 2003
- Influences of Methodological Variables on Susceptibility Testing of Caspofungin against Candida Species and Aspergillus fumigatusAntimicrobial Agents and Chemotherapy, 2003
- Pharmacokinetic and Pharmacodynamic Modeling of Anidulafungin (LY303366): Reappraisal of Its Efficacy in Neutropenic Animal Models of Opportunistic Mycoses Using Optimal Plasma SamplingAntimicrobial Agents and Chemotherapy, 2001
- Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin BJournal of Antimicrobial Chemotherapy, 2000
- Postantifungal Effects of Echinocandin, Azole, and Polyene Antifungal Agents against Candida albicans and Cryptococcus neoformansAntimicrobial Agents and Chemotherapy, 2000